1FW2 Stock Overview
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
WuXi Biologics (Cayman) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.77 |
| 52 Week High | HK$5.34 |
| 52 Week Low | HK$1.15 |
| Beta | 0.61 |
| 11 Month Change | -9.99% |
| 3 Month Change | 48.89% |
| 1 Year Change | -66.70% |
| 33 Year Change | n/a |
| 5 Year Change | -48.94% |
| Change since IPO | 65.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1FW2 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.0% | 0.9% | -0.02% |
| 1Y | -66.7% | 2.7% | 8.2% |
Return vs Industry: 1FW2 underperformed the German Life Sciences industry which returned 2% over the past year.
Return vs Market: 1FW2 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 1FW2 volatility | |
|---|---|
| 1FW2 Average Weekly Movement | 11.9% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1FW2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1FW2's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 12,435 | Chris Chen | www.wuxibiologics.com |
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.
WuXi Biologics (Cayman) Inc. Fundamentals Summary
| 1FW2 fundamental statistics | |
|---|---|
| Market cap | €7.29b |
| Earnings (TTM) | €348.86m |
| Revenue (TTM) | €2.27b |
20.9x
P/E Ratio3.2x
P/S RatioIs 1FW2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1FW2 income statement (TTM) | |
|---|---|
| Revenue | CN¥17.12b |
| Cost of Revenue | CN¥10.50b |
| Gross Profit | CN¥6.62b |
| Other Expenses | CN¥3.99b |
| Earnings | CN¥2.63b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.64 |
| Gross Margin | 38.66% |
| Net Profit Margin | 15.38% |
| Debt/Equity Ratio | 4.8% |
How did 1FW2 perform over the long term?
See historical performance and comparison